REGN668
R668-AD-0914
Phase 1 mab completed
Quick answer
REGN668 for Dermatitis is a Phase 1 program (mab) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Dermatitis
- Phase
- Phase 1
- Modality
- mab
- Status
- completed